4th Quarter - Report

THE MCMANUS GROUP for ZIMMER BIOMET

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, and S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024 Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.

LobbyistCovered position, as disclosed
LAWREN D GEER —
JOHN MCMANUS —
ALEX WHALEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 5349 (118th), H.R. 1691 (118th), S. 312 (118th), H.R. 972 (118th)

Health Issues HCR

Issues related to Artificial Intelligence approval in Medical Devices H.R.8818 - American privacy Rights Act of 2024

LobbyistCovered position, as disclosed
LAWREN D GEER —
JOHN MCMANUS —
ALEX WHALEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 8818 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.